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Hereditary spastic paraplegias (HSPs) are clinically and genetically heterogeneous neurological conditions. Their main pathogenicmech-
anisms are thought to involve alterations in endomembrane trafficking, mitochondrial function, and lipid metabolism. With a combi-
nation of whole-genome mapping and exome sequencing, we identified three mutations in REEP2 in two families with HSP: a missense
variant (c.107T>A [p.Val36Glu]) that segregated in the heterozygous state in a family with autosomal-dominant inheritance and a
missense change (c.215T>A [p.Phe72Tyr]) that segregated in trans with a splice site mutation (c.105þ3G>T) in a family with auto-
somal-recessive transmission. REEP2 belongs to a family of proteins that shape the endoplasmic reticulum, an organelle that was altered
in fibroblasts from an affected subject. In vitro, the p.Val36Glu variant in the autosomal-dominant family had a dominant-negative
effect; it inhibited the normal binding of wild-type REEP2 to membranes. The missense substitution p.Phe72Tyr, in the recessive family,
decreased the affinity of the mutant protein for membranes that, together with the splice site mutation, is expected to cause complete
loss of REEP2 function. Our findings illustrate how dominant and recessive inheritance can be explained by the effects and nature of
mutations in the same gene. They have also important implications for genetic diagnosis and counseling in clinical practice because
of the association of various modes of inheritance to this new clinico-genetic entity.Hereditary spastic paraplegias (HSPs) are clinically and
genetically heterogeneous inherited neurological disorders
mainly characterized by progressive spasticity and, often,
loss of vibration sense in the lower limbs.1,2 These symp-
toms can be associated in complicated forms of HSP with
various other neurological and extraneurological signs.2,3
The estimated prevalence varies from 1.27 to 9.6/
100,000.4,5 The main pathological characteristic of HSP
is the axonal degeneration in the long descending and
ascending tracts of the spinal cord, particularly the pyra-
midal tracts and the dorsal columns, and especially their
terminal portions. The clinical heterogeneity of HSP is
related to a notable genetic heterogeneity; indeed, more
than 50 genetic loci have been identified and mutations
have been found inmore than 30 genes.6–8 However, these
genes explain only 50% of the cases of HSP, indicating that
other genes remain to be discovered. The functions of the
proteins encoded by the known genes have suggested that
the pathophysiological mechanisms underlying expres-
sion of the disease may converge on a small number of
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function, myelination, or lipid metabolism.3,6–9
The endoplasmic reticulum (ER) is a continuous network
of membranous sheets and tubules. Its organization is
controlled mainly by two families of proteins that have
been associated with the pathophysiology of HSPs: the re-
ticulon and REEP/DP1/Yop1p families. The gene encoding
reticulon 2 (RNT2 [MIM 603183]) is mutated in the SPG12
(MIM 604805) subtype of HSP,10 and mutations in REEP1
(receptor expression-enhancing protein 1 [MIM 609139])
cause SPG31 (MIM 610250).11 The proteins of both fam-
ilies have two hydrophobic domains that are thought to
form hairpin loops generating curvature of the ER mem-
brane when inserted into the phospholipid bilayer.12–14
These proteins are thus crucial for the production and sta-
bilization of the highly curved ER tubules and the edges of
ER sheets.13 Accordingly, loss of Reep1 in a mouse model
affected the organization of the ER.14 Reticulon 2 and
REEP1 also interact with two other proteins, atlastin and
spastin, implicated in the pathophysiology of SPG3
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Here we report the identification of mutations in the
gene encoding another member of the REEP/DP1/Yop1p
family, receptor expression-enhancing protein 2 (REEP2),
in two families, one with autosomal-dominant HSP
and the other with autosomal-recessive inheritance of
the disease. In addition, we present evidence that loss of
the ability of REEP2 to bind to membranes underlies the
disease.
Two families with HSP were selected according to the
Harding’s criteria,1 after exclusion of alternative causes,
and were sampled for DNA extraction. All family members
were informed and signed consent according to the
Paris-Necker Ethics Committee approval (RBM INSERM
n01-29).
Family FSP200 is a French family with ten living affected
individuals, four at-risk subjects, and two healthy spouses
(Figure 1A and Table S1 available online). All affected sub-
jects had a homogeneous, pure HSP phenotype (spastic
gait and mild stiffness at rest) since childhood (mean age
at onset of 3.7 5 1.9 years). At the time of examination
(32.9 5 20.9 years), after a mean disease duration of
28.0 5 9.1 years, sphincter disturbance was noted in five
subjects, pes cavus in three, a slight postural tremor in
two, and decreased vibration sense at ankles in two. The in-
dex subject (FSP200-IV.4) also complained of diffuse pain
and problems with memory and concentration at age 59.
The disease progressed slowly as evaluated with the spastic
paraplegia rating scale16 in the index subject (scores of 19/
52 and 21/52 at ages 54 and 59, respectively). The three
subjects with the longest disease durations (43, 55, and
61 years) were still able to walk without help or with uni-
lateral assistance. No cerebellar syndrome, mental impair-
ment, or ocular abnormalities were observed. Mutations
in SPAST (SPG4) and HSPD1 (SPG13 [MIM 605280]) were
excluded by direct Sanger sequencing, and genome-wide
linkage mapping with SNP markers covering all chromo-
somes (Illumina LINKAGE_12 microarrays) was under-
taken to localize the mutation responsible for the disease,
as previously described.17 Linkage analysis, assuming a
dominant inheritance model with incomplete penetrance
set at 80%, identified 42 chromosomal regions covering a
total of 235 Mb putatively segregating with the disease:
eight regions with positive multipoint LOD scores ranging
from þ0.5 to þ2.1 on chromosomes 4, 5, 12, 19, and X
and 34 uninformative regions with LOD scores ranging
from 1.9 to þ0.1. Only one region overlapped with a
known SPG candidate region, SPG36 (MIM 613096).18
We used this information to filter the exome-sequenc-
ing data from three affected individuals (FSP200-IV.1,
FSP200-V.7, and FSP200-V.8) as described elsewhere.19 Var-
iants in the heterozygous state were selected according to
their quality (GATK quality score > 30),20 functional class
(nonsynonymous and/or affecting splicing), presence in
chromosomal regions with putative or nonexcluded link-
age, and frequency% 0.1% in publically available genomic
databases (dbSNP135, NHLBI). These criteria reduced the
list to two missense variants (Table S2): (1) c.483G>TThe Americ(p.Leu161Phe) in SERPINA1 (RefSeq accession number
NM_001002236.2) that was considered tolerated/benign
by SIFT, Mutation Taster, and PolyPhen-2 algorithms and
altered an amino acid not conserved in primates; and (2)
c.107T>A (p.Val36Glu) in REEP2 (RefSeq NM_016606.3,
Figures 1B and 1C), which segregated with the disease in
the family (Figure 1A), was predicted to be deleterious by
the same algorithms as above and affected an amino acid
conserved up to D. melanogaster and C. elegans and in the
paralogous human proteins REEP1, REEP3, and REEP4
(Figure 1D). This mutation was also absent from an in-
house exome data set of 2,615 individuals with various un-
related neurological disorders. Of note, one asymptomatic
subject with the mutation (FSP200-V.2, Figure 1A) was 23
years old at last examination and was considered to be
possibly affected because of brisk reflexes in the lower
limbs, pes cavus, and no plantar response, in the absence
of spastic gait.
Family FSP940 is a Portuguese family in which four
affected children were born of unaffected, nonconsangui-
neous parents (Figure 1A). One of these children died
before the genetic studies but was clinically assessed.
The four affected subjects had a pure HSP phenotype
(Table S1) since the age of 2, which worsened with time,
but not at the same rate; the affected individuals needed
two canes to walk after disease durations varying from
6 to 23 years. To identify the mutations responsible for
HSP in this kindred, we used the same strategy as for
family FSP200, a combination of whole-genome linkage
mapping and exome sequencing. The whole-genome
linkage analysis, assuming a fully penetrant recessive
mode of inheritance, detected 433 Mb of the genome
that segregated in all affected subjects at an identical state:
in five chromosomal regions, multipoint LOD scores
ranged from þ0.5 to þ0.9; in six regions, the multipoint
LOD scores reached the maximal expected value of þ1.2
in the pedigree (chromosomes 1, 2, 5, 9, 10, 15); 75
regions were uninformative with LOD scores between
1.9 and þ0.2. Some of these regions partially overlapped
with known autosomal-recessive or X-linked SPG loci,
namely SPG16 (MIM 300266), SPG27 (MIM 609041), and
SPG45 (MIM 613162).21–23 Exome sequencing in subjects
FSP940-III.2 and FSP940-III.3 was then performed as in
family FSP200. The same analytic criteria were applied
except that we focused on homozygous or compound
heterozygous variants (frequency < 1% in public data-
bases) in conformity with the most likely mode of inheri-
tance in this kindred (Table S2). No homozygous variants
were found in the putatively linked or uninformative re-
gions, and only one gene, REEP2, had two heterozygous
mutations in both affected cases: (1) a c.105þ3G>Tchange
that was predicted (Splice Site Finder algorithm) to alter
the 50 consensus splicing sequence of intron 2; and (2)
a c.215T>A missense change (p.Phe72Tyr) (Figure 1C),
predicted to be deleterious by PolyPhen-2 and Mutation
Taster (and tolerated by SIFT) and affecting an amino
acid conserved during evolution of REEP2 (up to thean Journal of Human Genetics 94, 268–277, February 6, 2014 269
H.sapiens MVSWIISRLVVLIFGTLYPAYSSYKAVKTKNVKEYVKWMMYWIVFAFFTTAETLTDIVLS–WFPFYFELKIAFVIWLLSPYTKGSSVLYRKFVHPTLSNKEKEIDEYIT 108
M.musculus MVSWIISRLVVLIFGTLYPAYSSYKAVKTKNVKEYVKWMMYWIVFAFFTTAETLTDIILS–WFPFYFELKIAFVIWLLSPYTKGSSVLYRKFVHPTLSNKEKEIDEYIT 108
G.gallus MVSWIISRLVVLIFGTLYPAYSSYKAVKTKNVKEYVKWMMYWIVFAFFTTAETLTDIVLS–WFPFYFELKIAFVIWLLSPYTKGSSVLYRKFVHPTLSNKEKEIDEYIT 108
X.tropicalis MVSWIISRLVVLIFGTLYPAYSSYKAVKTKNVKEYVKWMMYWIVFAFFTTAETLTDIILS–WFPFYFELKIAFVIWLLSPYTKGSSVLYRKFVHPTLSSKEKEIDEYIA 108
D.rerio MVSWIISRMVVLAFGTLYPAYSSYKAVKTKNVKEYVKWMMYWIVFALFTTAETITDMLLS–WFPFYFELKIAFVIWLLSPYTKGSSVLYRKFVHPTLSNKEREIDEYIT 108
D.melanogaster MISSLFSRLIILFCGTLYPAYASYKAVRTKDVKEYVKWMMYWIVFAFFTCIETFTDIFIS–WLPFYYEVKVALVFWLLSPATKGSSTLYRKFVHPMLTRHEQEIDEYVN 108
C.elegans M-SETLSRLLIITAGTLYPAYRSYKAVRTKDTREYVKWMMYWIVFAIYSFLENLLDLVLAFWFPFYFQLKIVFIFWLLSPWTKGASILYRKWVHPTLNRHEKDIDALLE 108
* *  :**::::  ******* *****:**:.:*************:::  *.: *:.:: *:***:::*:.:::***** ***:* ****:*** *. :*::**  :
REEP1   1 MVSWIISRLVVLIFGTLYPAYYSYKAVKSKDIKEYVKWMMYWIIFALFTTAETFTDIFLCWFPFYYELKIAFVAWLLSPYT-KGSSLLYRKFVHPTLSSKEKEIDDCLV 108
REEP2   1 MVSWIISRLVVLIFGTLYPAYYSYKAVKSKDIKEYVKWMMYWIIFALFTTAETFTDIFLCWFPFYYELKIAFVIWLLSPYT-KGSSVLYRKFVHPTLSNKEKEIDEYIT 108
REEP3   1 MVSWMISRAVVLIFGTLYPAYYSYKAVKSKDIKEYVKWMMYWIIFALFTTAETFTDIFLCWFPFYYELKIAFVIWLLSPYT-KGASLIYRKFLHPLLSSKEREIDDYIV 108
REEP4   1 MVSWMICRLVVLVFGMLCPAYASYKAVKTKNIREYVRWMMYWIVFALFMAAEIVTDIFISWFPFYYEIKMAFVLWLLSPYT-KGASLLYRKFVHPSLSRHEKEIDAYIV 108
REEP5  49  LVFGYGASLLCNLIGFGYPAYISIKAIESPNKEDDTQWLTYWVVYGVFSIAEFFSDIFLSWFPFYYMLKCGFLLWCMAPSPSNGAELLYKRIIRPFFLKHESQMDSVVK 156
REEP6  50 LLFGYGASLLCNLIGFVYPAYASIKAIESPSKDDDTVWLTYWVVYALFGLAEFFSDLLLSWFPFYYVGKCAFLLFCMAPRPWNGALMLYQRVVRPLFLRHHGAVDRIMN 155
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Figure 1. Pedigrees and Segregation of the REEP2 Mutations
(A) Pedigrees of two families with hereditary spastic paraplegia. Segregation of the mutations is indicated (plus sign indicates wild-type,
M indicates mutation). Affected individuals are designated by black squares (men) or circles (women). Sampled individuals are desig-
nated by an asterisk (*). Subjects with unknown status are designated with a question mark. The arrow indicates the index subject.
(B) Schematic representation of the gene showing the sites of the mutations.
(C) Electrophoregrams showing the mutations.
(D) Conservation of amino acids in the N-terminal domain of REEP2 according to the phylogenic evolutionary tree (top) and in com-
parison with other members of the REEP family in H. sapiens. The positions of the missense mutations are shown by arrows. Conserved
amino acids are in yellow (among species), red (among all REEP proteins), or blue (among members of the REEP1–REEP4 subfamily).
Horizontal bars represent the hydrophobic segments of the proteins.
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zebrafish) and in all members of the REEP family
(Figure 1D). Both mutations were absent from the exome
of 76 healthy controls and 2,615 individuals affected by
various neurological disorders. The effect of the splice
site mutation could not be verified in mRNA from affected
subjects.
The three mutations identified in REEP2 are likely to be
pathogenic for the following reasons. (1) They were absent
from a large series of controls and local or public exomes,
including 500 index subjects with hereditary spastic para-
plegia or peripheral neuropathy. (2) They segregated with
the disease in the heterozygous (c.107T>A [p.Val36Glu])
or compound heterozygous (c.[105þ3G>T; 215T>A], r.?;
p.Phe72Tyr) state according to the type of inheritance
suspected in the pedigrees. (3) They were the only variants
remaining after filtering of the exome data obtained
with high base coverage (Table S2). (4) The mutations led
(theoretically) to missplicing (c.105þ3G>T) or affected
amino acids that are highly conserved during evolution,
even among paralogous members of the REEP family, sug-
gesting that they impair the functions of the protein. (5)
Another member of the REEP family, REEP1, is mutated
in SPG31 HSP11 and the two REEP2 missense variants are
located in the highly conserved hydrophobic N-terminal
domain of the protein, as are all of the missense mutations
reported so far in REEP1.11,24–27
REEP2 is highly expressed in brain and testis.28 Its prod-
uct, REEP2, together with REEP1, belongs to the DP1/
Yop1p family of ER-shaping proteins. The proteins of this
family contain two highly conserved hydrophobic do-
mains at their N terminus, which have been suggested to
form hairpins that insert into membranes and promote
homo- or hetero-oligomerization.15,29 Insertion of hair-
pins into membranes can modulate their curvature;12–14
loss of Reep1 in a mouse model indeed affected the orga-
nization of the ER.14 Furthermore, several proteins of the
REEP/DP1/Yop1p family have been shown to interact
with microtubules. This interaction is mediated by the
carboxyl terminus of the protein in REEP115 or by basic res-
idues between the two hydrophobic domains in REEP3
and REEP4.30 Because the p.Val36Glu and p.Phe72Tyr var-
iants associated with HSP in families FSP200 and FSP940
affect conserved residues in the N-terminal domain of
REEP2, we hypothesized that these variants may affect
the ER-shaping properties of REEP2.
We first analyzed the consequences of the p.Val36Glu
substitution on the subcellular localization of the protein.
When we overexpressed V5-tagged REEP2 in COS7 cells,
both the wild-type and the p.Val36Glu variants were
distributed in a dot-like pattern along both the ER and
the microtubules (Figure S1). Of note, unlike previous
observations,15 REEP2 rarely induced the formation of
microtubule bundles (less than 2% of cells) and this
occurred only in cells expressing the highest levels of
REEP2. The subcellular localization of REEP2 was there-
fore consistent with a possible role for the protein in ER
shaping.The AmericWe therefore analyzed ER morphology in primary fibro-
blasts from the affected subject FSP200-IV.4 that expressed
the p.Val36Glu variant. The levels of REEP2 in FSP200-
IV.4’s fibroblasts were similar to those in age-matched
control fibroblasts (Figure 2A). We then transfected the
fibroblasts with a vector allowing expression of GFP-
Sec61b12 to label the whole ER and immunolabeled them
with an antibody against the ER sheet protein CLIMP-
63.13 In control fibroblasts, CLIMP-63 immunoreactivity
was concentrated around the nucleus and was almost
absent from peripheral ER. In contrast, in FSP200-IV.4’s fi-
broblasts, CLIMP-63 staining was interspersed throughout
the GFP-Sec61b labeling (Figure 2B). In FSP200-IV.4’s
fibroblasts, the percentage of the cellular area occupied
by CLIMP-63 staining was significantly increased
compared to control fibroblasts, indicating that CLIMP-
63 was distributed more widely throughout peripheral ER
and that ER sheets were expanded (Figure 2C). To further
investigate the consequences of the p.Val36Glu substitu-
tion in REEP2, we analyzed the fibroblasts by transmission
electron microscopy (Figure 2D) as previously described.31
In control fibroblasts, most ER structures were 20 to 60 nm
thick, as expected.13 In contrast, ER tubules thinner than
20 nm and swollen ER sheets thicker than 100 nm were
more numerous in fibroblasts containing mutant REEP2
(Figure 2E).
Because the level of REEP2 in FSP200-IV.4’s fibroblasts
was similar to control level (Figure 2A), the observed
phenotype could be due either to haploinsufficiency
caused by loss of function of the p.Val36Glu variant or
to a dominant-negative gain of function. To test these
hypotheses, we downregulated the expression of REEP2
in COS7 cells by using shRNA vectors (Figure 3A) and
immunostained the cells with antibodies against calreticu-
lin and CLIMP-63 to visualize the organization of the ER.
As observed in FSP200-IV.4’s fibroblasts, CLIMP-63 stain-
ing was widely distributed after downregulation of
REEP2 (Figures 3B and 3C). We then tested the effect of
the p.Val36Glu variant on ER morphology in COS7 cells
by overexpressing wild-type or p.Val36Glu REEP2. The
distribution of CLIMP-63 was similar in nontransfected
cells and those overexpressing wild-type REEP2 but was
more widespread in cells overexpressing p.Val36Glu
REEP2 (Figures 3D and 3E). This demonstrated that over-
expression of p.Val36Glu REEP2 led to a phenotype
similar to that observed in fibroblasts from the affected
subject (Figure 2B).
The similarity between the phenotypes induced by
downregulation of REEP2 or overexpression of the
p.Val36Glu REEP2 variant suggested that p.Val36Glu
might inhibit the function of endogenous wild-type
REEP2, possibly by interfering with its ability to form olig-
omers like other proteins of the REEP/DP1/Yop1p fam-
ily.15,29 To investigate how the p.Val36Glu variant might
affect REEP2, we focused on properties probably mediated
by its N-terminal domain: protein-protein interactions,
binding to microtubules, and binding to membranes.an Journal of Human Genetics 94, 268–277, February 6, 2014 271
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Figure 2. REEP2 Is Implicated in ER Morphogenesis
(A) Immunoblot showing the amount of endogenous REEP2, actin, and CLIMP-63 in fibroblasts from a control and family member
FSP200-IV.4.
(B) Control and FSP200-IV.4 fibroblasts were transfected with vectors directing expression of GFP-Sec61b (red, false color) and immuno-
stained with antibodies against CLIMP-63 (green).
(C) Quantification of the area occupied by CLIMP-63 staining in cells (control n¼ 50, FSP200-IV.4 n¼ 57). Data represent mean5 SEM.
***p < 0.0001, t test.
(D) Transmission electron micrographs of control and FSP200-IV.4 fibroblasts. Asterisk indicates swollen ER; arrowhead points to a very
thin ER sheet.
(E) Quantification of the thickness of ER sheets in fibroblasts. Control n ¼ 210, FSP200-IV.4 n ¼ 237. ***p ¼ 4 3 108,
chi-square test.We first investigated whether the p.Val36Glu variant
modified an interaction with wild-type REEP2 by cotrans-
fecting COS7 cells with vectors directing expression of
V5- and GFP-tagged REEP2. Both proteins coimmunopreci-
pitated with an anti-V5 antibody, and the p.Val36Glu
variant did not prevent the interaction between themutant
and the wild-type protein (Figure S2A). We then cotrans-
fected cells with vectors directing expression of REEP2 in
combination with atlastin-1, M1-spastin, or REEP1. Atlas-
tin, M1-spastin, and REEP1 coimmunoprecipitated with
REEP2, even in the presence of p.Val36Glu REEP2 variant
(Figures S2B–S2D). We also assessed the interaction of
REEP2 with microtubules in extracts from COS7 cells
overexpressing REEP2, by using an in vitro microtubule
pull-down assay. Both wild-type and p.Val36Glu REEP2
interacted with microtubules (Figure S3).
Finally, to monitor the interaction of REEP2 with
membranes, we performed a subcellular fractionation in
COS7 cells expressing V5-tagged REEP2 as previously
described.15 Wild-type and p.Val36Glu REEP2 sedimented
in the membrane fraction (Figure 4A). Upon alkaline
extraction,15 both wild-type and mutated REEP2 disso-272 The American Journal of Human Genetics 94, 268–277, Februaryciated from membranes in a manner similar to the
membrane-associated protein calreticulin (Figure 4B).
This suggests that REEP2, in contrast to REEP1, is not an in-
tegral membrane protein. The binding of REEP2 to mem-
brane could thus be mediated either by a labile interaction
or by interaction with integral membrane proteins such as
REEP1, atlastin, or spastin. To discriminate among these
possibilities, we purified recombinant REEP2 from E. coli
extracts as previously described32 and used a liposome
flotation assay to analyze its ability to bind to membranes
in the absence of any other protein.32 We observed that a
portion of wild-type REEP2 bound to membranes, whereas
the p.Val36Glu variant did not (Figures 4C–4E). Impor-
tantly, when the assay was performed with an equimolar
mixture of wild-type and p.Val36Glu REEP2, the interac-
tion with membranes was abolished, suggesting that the
presence of p.Val36Glu variant impeded binding of the
wild-type protein to membranes.
The data obtained with the p.Val36Glu variant show
that REEP2 must interact with integral membrane pro-
teins to sediment in the subcellular membrane fraction.
This interaction might concentrate REEP2 in proximity6, 2014
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Figure 3. REEP2 Downregulation Leads to Expansion of ER Sheets
(A) COS7 cells were transfected with vectors directing the expression of shRNAs obtained from Sigma (shRNA REEP2_A
hairpin sequence: CCCAGCCTATTCTTCCTACAACTCGAGTTGTAGGAAGAATAGGCTGGGT, shRNA REEP2_B hairpin sequence:
ACTGGCTTCCAAGACACTGAACTCGAGTTCAGTGTCTTGGAAGCCAGTT). Cell lysates were immunoblotted with antibodies against
endogenous REEP2 and actin.
(B) COS7 cells in which endogenous REEP2was downregulated by shRNAwere immunostained with antibodies against the endoplasmic
reticulum marker calreticulin and CLIMP-63 that labels ER sheets.
(C) Quantification of the area occupied by CLIMP-63 staining in cells. n > 50 cells in three independent experiments. Data represent
mean5 SEM. ***p < 0.001, one-way ANOVA.
(D) COS7 cells were transfected with vectors directing the expression of wild-type or V5-tagged p.Val36Glu REEP2. Cells were immuno-
stained with anti-V5 and anti-CLIMP-63 antibodies.
(E) Quantification of the cellular area occupied by CLIMP-63 staining. n> 50 cells per condition. Data representmean5 SEM. *p< 0.05,
one-way ANOVA.to membranes. However, the ability of REEP2 to interact
directly with membranes is more probably due to inser-
tion of its hydrophobic regions into membranes, modu-
lating membrane curvature as shown for REEP1.14
The simultaneous presence of the p.Val36Glu variant
and wild-type REEP2, which recapitulates the situation
observed in FSP200 family, abolishes the direct interaction
of the latter with membranes, thus preventing REEP2
from regulating membrane curvature in ER tubules or at
the edges of ER sheets where the protein is localized.
These data are consistent with the ER sheet expansion
and ER swelling observed in cells expressing p.Val36Glu
REEP2 and confirm that this variant induces loss of func-
tion of the wild-type REEP2 through a dominant-negative
effect. It could thus underlie the physiopathology of HSP
in family FSP200.
We then investigated whether such a loss-of-function
mechanism could also occur in family FSP940, withThe Americtwo heterozygous mutations in REEP2: a splice-site
mutation and missense change affecting a conserved
residue (p.Phe72Tyr). Because the splice site mutation
very probably prevents the expression of a functional pro-
tein, we focused on the consequences of the p.Phe72Tyr
substitution in REEP2. After overexpression in COS7
cells, V5-tagged p.Phe72Tyr REEP2 was distributed along
ER and microtubules (Figure S1) like the wild-type pro-
tein. Microtubule pull-down experiments performed
with extracts from COS7 cells overexpressing p.Phe72Tyr
REEP2 demonstrated that the p.Phe72Tyr variant was
able to bind to microtubules like the wild-type pro-
tein (Figure S3). Coimmunoprecipitation of REEP1 and
V5-tagged REEP2 from COS7 cells overexpressing these
proteins showed that p.Phe72Tyr REEP2 coimmunopreci-
pitated about 25% less REEP1 than did wild-type REEP2
or the p.Val36Glu variant (Figures 4F and 4G). In sub-
cellular fractionation experiments, p.Phe72Tyr REEP2an Journal of Human Genetics 94, 268–277, February 6, 2014 273
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Figure 4. Interaction of REEP2 with REEP1 and Membranes
(A) Homogenates (Homog.) fromV5-tagged REEP2-expressing COS7 cells were separated into soluble (Sol.) andmembrane (Memb.) frac-
tions and then immunoblotted to detect REEP2 (anti-V5 antibody), the membrane marker calnexin, and the cytosolic marker tubulin.
(B) Lysedmembranes from V5-tagged REEP2-expressing COS7 cells were subjected to alkaline extraction, and the soluble and pellet frac-
tions were analyzed by immunoblot to detect REEP2 (anti-V5 antibody), the soluble protein calreticulin, and the integral membrane
protein calnexin.
(C) Schema representing the liposome flotation experiment. Liposomes were prepared by mixing chloroform solutions of brain phos-
phatidylcholine and phosphatidylserine (Avanti Polar Lipids) in 75:25 ratio. After drying the lipids under nitrogen, they were resus-
pended in 100 mM NaCl, 10 mM Tris (pH 7.4) and sonicated. Liposomes were incubated with recombinant protein for 30 min at
22C, and then mixed with equal amount of 50% sucrose in 100 mM NaCl, 10 mM Tris (pH 7.4). The mixture was overlaid with
40 ml of 15% sucrose solution. After centrifugation, the liposomes were collected at the top of the upper phase (top) and unbound pro-
teins in the lower phase (bottom).
(D) Liposome flotation assay with wild-type REEP2, p.Val36Glu REEP2, p.Phe72Tyr REEP2, and an equimolar amount of wild-type and
p.Val36Glu REEP2 analyzed by immunoblot with an antibody raised against REEP2.
(E) Quantification of the association of recombinant REEP2withmembranes. Data representmean5 SEM (n¼ 4). ***p< 0.001, one-way
ANOVA.
(F) V5-tagged REEP2 and HA-tagged REEP1 were coexpressed in COS-7 cells and REEP2 immunoprecipitated with an anti-V5 antibody.
The eluates were analyzed by immunoblot.
(G) Quantification coimmunoprecipitation of HA-REEP1 with REEP2. The p.Phe72Tyr variant in REEP2 decreased the interaction of
REEP2 with REEP1. Data represent mean5 SEM (n ¼ 3). *p < 0.05.sedimented with membranes (Figure 4A). It should be
noted that these experiments were performed in the
presence of the wild-type protein expressed by COS7 cells.
This could partially mask the pathogenic effect of the
mutation in cells of affected members of family FSP940
in which the second mutated allele is probably degraded274 The American Journal of Human Genetics 94, 268–277, Februaryat the mRNA level, resulting in downregulation of the pro-
tein. We then assessed the ability of the recombinant pro-
tein to directly bind to liposome membranes in an in vitro
assay. The p.Phe72Tyr variant associated with membranes,
but with a much lower affinity than the wild-type
protein (Figures 4C–4E), suggesting that the p.Phe72Tyr6, 2014
substitution induced the loss of this function. Because the
mutation encoding this variant is associated in transwith a
splice site mutation, we hypothesize that it would cause a
strongly decreased association of REEP2 with membrane
in affected members of family FSP940, which fits well
with the autosomal-recessive inheritance observed in
this family.
In conclusion, we have identified mutations in REEP2
in two families with relatively pure, early-onset HSP,
one with autosomal-dominant and the other with
autosomal-recessive transmission. In family FSP200, we
demonstrated that the mutant protein inhibited the
direct binding of wild-type REEP2 to membranes, in agree-
ment with a dominant-negative effect of the mutation on
this property. In family FSP940, the splice site mutation is
expected to decrease expression of the protein by 50%,
whereas the second mutation, expressed in trans, affects
the membrane binding properties of the protein. This
would lead to a complete loss of membrane binding by
REEP2. The loss of interaction of REEP2 with membranes
could thus be a common mechanism in autosomal-domi-
nant and -recessive inherited cases of this HSP subtype.
The ability of REEP2 to bind directly to membranes is
probably due to the insertion of its hydrophobic domains
into the phospholipid bilayer. As shown for other mem-
bers of this family of proteins,12–14 this property might
regulate the curvature of ER membranes where the pro-
tein resides. Loss of this function would lead to a decrease
in ER membrane curvature, explaining the expansion of
ER sheets and ER swelling observed in fibroblasts from
an affected individual. Other proteins of the REEP/DP1/
Yop1p family probably partially compensate for the loss
of REEP2 function, explaining why we did not detect
the massive proliferation of ER sheet observed in
S. cerevisiae lacking both reticulon and Yop1p.12 We also
cannot exclude that other functions of the REEP2 protein
may contribute to the phenotype, as for example, the
reduced interaction of p.Phe72Tyr REEP2 with REEP1
shown in our study. REEP2 has also been proposed to
modulate the trafficking of proteins from ER to Golgi.33
It is thus possible that the loss of REEP2 association
with membrane and the alteration of ER morphology
observed in cells of affected subjects would change this
trafficking activity and that this could also contribute to
the pathology.
These findings illustrate how the nature of the muta-
tions and their effects determine the mode of transmission
of a genetic trait. Various modes of transmission associated
to mutations in a single gene have been shown in other
diseases,34 including other forms of spastic paraplegia,
e.g., SPG7 (MIM 607259).35 One can speculate that deci-
phering the deleterious effects of the mutations in SPG7
(MIM 602783) would explain why dominant inheritance
is associated with isolated optic atrophy whereas recessive
inheritance leads to a more complex phenotype including
spastic paraplegia, optic atrophy, and various degrees of
cerebellar involvement.The AmericSupplemental Data
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